Bristol Myers Squibb (NYSE:BMY) Shares Down 1.9% – Should You Sell?

Bristol Myers Squibb Company (NYSE:BMY)’s share price dropped 1.9% during trading on Tuesday . The company traded as low as $53.88 and last traded at $54.2030. Approximately 15,343,178 shares were traded during trading, an increase of 17% from the average daily volume of 13,144,328 shares. The stock had previously closed at $55.26.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: BMY signed a collaboration with Microsoft to use its AI-enabled radiology platform to speed early detection of lung cancer — a strategic move that could strengthen diagnostics, clinical trial readouts and long-term oncology positioning. Bristol Myers partners with Microsoft for AI-driven lung cancer detection
• Positive Sentiment: Scotiabank highlighted BMY as an appealing 2026 investment and raised its price target (reported lift to $60 from $53), which could support investor sentiment if other analysts follow. Scotiabank Notes Bristol-Myers Squibb Company (BMY) as Appealing Investment in 2026
• Positive Sentiment: BMS extended a deal with Syngene, keeping manufacturing and R&D continuity intact — a modest operational positive for supply chain stability. BMS extends deal with Syngene
• Neutral Sentiment: A Zacks comparison piece contrasts BMY with GSK on portfolio and prospects; useful for longer-term allocation decisions but not an immediate catalyst. BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now?
• Neutral Sentiment: Coverage in ETF/blue‑chip lists and investor videos (dividend ETF roundups, “top blue‑chip” buys) reinforces BMY’s image as a reliable large-cap dividend/defensive healthcare name but is more background than a fresh catalyst. 3 Dividend Income ETFs That Offer High Yields And Growth 2 Top Blue-Chip Stocks to Buy and Hold in 2026
• Neutral Sentiment: Mentions in broader investor roundups (e.g., MarketBeat on Buffett-related names) keep BMY in view for income/ value investors but don’t constitute direct drivers. 2 Buffett Stocks to Load Up On—And 1 to Ditch (BMY)

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BMY. Citigroup reissued a “neutral” rating and set a $53.00 price objective (up from $45.00) on shares of Bristol Myers Squibb in a research note on Wednesday, January 7th. Guggenheim reissued a “buy” rating on shares of Bristol Myers Squibb in a report on Tuesday, December 23rd. HSBC reissued a “hold” rating and set a $53.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. Morgan Stanley restated an “underweight” rating and issued a $37.00 price target (up previously from $36.00) on shares of Bristol Myers Squibb in a research report on Friday, December 12th. Finally, Scotiabank restated a “sector perform” rating and issued a $60.00 target price (up previously from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Seven research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $56.86.

Bristol Myers Squibb Stock Performance

The stock’s 50-day simple moving average is $52.07 and its 200 day simple moving average is $48.19. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. The stock has a market capitalization of $110.34 billion, a price-to-earnings ratio of 18.31 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.11. The firm had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.75 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The company’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter last year, the company posted $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be issued a dividend of $0.63 per share. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a yield of 4.6%. The ex-dividend date is Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 85.14%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Trifecta Capital Advisors LLC bought a new stake in Bristol Myers Squibb during the 2nd quarter valued at $25,000. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at $25,000. Harbor Capital Advisors Inc. lifted its holdings in shares of Bristol Myers Squibb by 107.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 313 shares during the last quarter. REAP Financial Group LLC grew its holdings in shares of Bristol Myers Squibb by 202.8% during the 2nd quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 428 shares during the last quarter. Finally, KERR FINANCIAL PLANNING Corp purchased a new stake in Bristol Myers Squibb during the 3rd quarter valued at $35,000. 76.41% of the stock is owned by institutional investors and hedge funds.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.